RPTX / Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround

Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, comb more_horizontal

The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to thi more_horizontal

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal

Cathie Wood's ARK Genomic Revolution ETF is a top shareholder of Repare Therapeutics. Wood, along with several Wall Street analysts, hold an overtly b more_horizontal

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compare more_horizontal

The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric more_horizontal

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do t more_horizontal

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average? more_horizontal